[Therapeutic drug monitoring of valproate].
Valproic acid is an anticonvulsant drug available in France since 1967. It is a broad spectrum molecule indicated in various forms of epilepsy of the adult and the child, but it is also prescribed in the treatment of different other pathologies of nervous system. The divalproate sodium is indicated in the treatment of bipolar disorders. The valproic acid is marketed under various pharmaceutical forms, with different corresponding tmax values. But, whatever the administered preparation, the circulating active molecule is the ion valproate. Elimination half-life is from 11 to 20 h. Metabolization of valproate is important and represents its main route of elimination. Valpromide is comparable to a prodrug which metabolizes in valproate. The inter and intraindividual variability of the plasma concentrations are important. Several studies show a concentration-effect relationship, but two interventional trials ended in the lack of interest of the Therapeutic Drug Monitoring (TDM), although it is of current practice. However, numerous drug interactions may modify the plasma concentrations of valproate. The therapeutic range is from 50 to 100 mg/L (346-693 micromol/L). The level of proof of the interest of the TDM for this molecule was estimated in: recommended.
Bentué-Ferrer
Danièle
D
Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France. daniele.bentue-ferrer@univ-rennes1.fr
Tribut
Olivier
O
Verdier
Marie-Clémence
MC
D000818:Animals; D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000523:psychology; D014635:Valproic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000927:Anticonvulsants; D014635:Valproic Acid